Renal microvascular lesions in lupus nephritis

References

• D’Agati V. Renal disease in systemic lupus erythematosus, mixed connective tissue disease, Sjogren’s syndrome, and rheumatoid arthritis. Philadephia (PA): Wolters Kluwer 2007.
   Google Scholar
• Wu LH, Yu F, Tan Y, et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int. 2013;83(4):715–723.
   PubMed Web of Science ®Google Scholar
• Barber C, Herzenberg A, Aghdassi E, et al. Evaluation of clinical outcomes and renal vascular pathology among patients with lupus. CJASN. 2012;7(5):757–764.
   PubMed Web of Science ®Google Scholar
• Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521–530.
   PubMed Web of Science ®Google Scholar
• Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789–796.
   PubMed Web of Science ®Google Scholar
• Atehortua L, Rojas M, Vasquez GM, et al. Endothelial alterations in systemic lupus erythematosus and rheumatoid arthritis: potential effect of monocyte interaction. Mediators Inflamm. 2017;2017:9680729.
   PubMed Web of Science ®Google Scholar
• Appel GB, Pirani CL, D’Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol. 1994;4(8):1499–1515.
   PubMed Web of Science ®Google Scholar
• Mejia-Vilet JM, Cordova-Sanchez BM, Uribe-Uribe NO, et al. Prognostic significance of renal vascular pathology in lupus nephritis. Lupus. 2017; 26:1042–1050.
   PubMed Web of Science ®Google Scholar
• Narshi CB, Giles IP, Rahman A. The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus? Lupus. 2011;20(1):5–13.
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340(2):115–126.
   PubMed Web of Science ®Google Scholar
• Cieslik P, Hrycek A, Klucinski P. Vasculopathy and vasculitis in systemic lupus erythematosus. Pol Arch Med Wewn. 2008;118:57–63.
   PubMedGoogle Scholar
• Renaudineau Y, Dugue C, Dueymes M, et al. Antiendothelial cell antibodies in systemic lupus erythematosus. Autoimmun Rev. 2002;1(6):365–372.
   PubMedGoogle Scholar
• Brandt KJ, Kruithof EK, de Moerloose P. Receptors involved in cell activation by antiphospholipid antibodies. Thromb Res. 2013;132(4):408–413.
   PubMed Web of Science ®Google Scholar
• Gomez-Zumaquero JM, Tinahones FJ, De Ramon E, et al. Association of biological markers of activity of systemic lupus erythematosus with levels of anti-oxidized low-density lipoprotein antibodies. Rheumatology (Oxford). 2004;43(4):510–513.
   PubMed Web of Science ®Google Scholar
• Abe H, Tsuboi N, Suzuki S, et al. Anti-apolipoprotein A-I autoantibody: characterization of monoclonal autoantibodies from patients with systemic lupus erythematosus. J Rheumatol. 2001;28(5):990–995.
   PubMed Web of Science ®Google Scholar
• Huang J, Han SS, Qin DD, et al. Renal interstitial arteriosclerotic lesions in lupus nephritis patients: a cohort study from China. PLoS One. 2015;10(11):e0141547.
   PubMed Web of Science ®Google Scholar
• Bhatia VK, Yun S, Leung V, et al. Complement C1q reduces early atherosclerosis in low-density lipoprotein receptor-deficient mice. Am J Pathol. 2007;170(1):416–426.
   PubMed Web of Science ®Google Scholar
• Buono C, Come CE, Witztum JL, et al. Influence of C3 deficiency on atherosclerosis. Circulation. 2002;105(25):3025–3031.
   PubMed Web of Science ®Google Scholar
• Matthijsen RA, de Winther MP, Kuipers D, et al. Macrophage-specific expression of mannose-binding lectin controls atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 2009;119(16):2188–2195.
   PubMed Web of Science ®Google Scholar
• Thacker SG, Berthier CC, Mattinzoli D, et al. The detrimental effects of IFN-alpha on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. JI. 2010;185(7):4457–4469.
   Google Scholar
• Goossens P, Gijbels MJ, Zernecke A, et al. Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metabol. 2010;12(2):142–153.
   PubMed Web of Science ®Google Scholar
• McLaren JE, Ramji DP. Interferon gamma: a master regulator of atherosclerosis. Cytokine Growth Factor Rev. 2009;20:125–135.
   PubMed Web of Science ®Google Scholar
• Kaplan MJ. Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol. 2011;7(12):691–699.
   PubMed Web of Science ®Google Scholar
• Knight JS, Subramanian V, O’Dell AA, et al. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann Rheum Dis. 2015;74(12):2199–2206.
   PubMed Web of Science ®Google Scholar
• Ding Y, Liao W, Yi Z, et al. Association of miRNA-145 expression in vascular smooth muscle cells with vascular damages in patients with lupus nephritis. Int J Clin Exp Pathol. 2015;8(10):12646–12656.
   PubMed Web of Science ®Google Scholar
• Sun W, Jiao Y, Cui B, et al. Immune complexes activate human endothelium involving the cell-signaling HMGB1-RAGE axis in the pathogenesis of lupus vasculitis. Lab Invest. 2013;93(6):626–638.
   PubMed Web of Science ®Google Scholar
• Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007;8(5):487–496.
   PubMed Web of Science ®Google Scholar
• Urbonaviciute V, Furnrohr BG, Meister S, et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med. 2008;205(13):3007–3018.
   PubMed Web of Science ®Google Scholar
• Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science (New York, NY). 1999;284(5421):1835–1837.
   Google Scholar
• Ronnblom L, Alm GV. The natural interferon-alpha producing cells in systemic lupus erythematosus. Hum Immunol. 2002;63:1181–1193.
   PubMed Web of Science ®Google Scholar
• Bave U, Magnusson M, Eloranta ML, et al. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol. 2003;171:3296–3302.
   PubMed Web of Science ®Google Scholar
• Kuroki A, Shibata T, Honda H, et al. Glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis, membranous lupus nephritis, and idiopathic membranous nephropathy. Intern Med. 2002;41(11):936–942.
   PubMed Web of Science ®Google Scholar
• Satoskar AA, Brodsky SV, Nadasdy G, et al. Discrepancies in glomerular and tubulointerstitial/vascular immune complex IgG subclasses in lupus nephritis. Lupus. 2011;20(13):1396–1403.
   PubMed Web of Science ®Google Scholar
• Ricklin D, Hajishengallis G, Yang K, et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11(9):785–797.
   PubMed Web of Science ®Google Scholar
• Song D, Wu LH, Wang FM, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013;15:R12.
   PubMed Web of Science ®Google Scholar
• Cohen D, Koopmans M, Kremer Hovinga IC, et al. Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis. Arthritis Rheum. 2008;58(8):2460–2469.
   PubMedGoogle Scholar
• Shen Y, Chen XW, Sun CY, et al. Association between anti-beta2 glycoprotein I antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: a prospective study of 155 cases. Lupus. 2010;19(10):1195–1203.
   PubMed Web of Science ®Google Scholar
• Chua JS, Baelde HJ, Zandbergen M, et al. Complement factor C4d is a common denominator in thrombotic microangiopathy. JASN. 2015;26(9):2239–2247.
   Web of Science ®Google Scholar
• Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun. 2000;15(2):145–151.
   PubMed Web of Science ®Google Scholar
• Krone KA, Allen KL, McCrae KR. Impaired fibrinolysis in the antiphospholipid syndrome. Curr Rheumatol Rep. 2010;12(1):53–57.
   PubMedGoogle Scholar
• Yang YH, Chien D, Wu M, et al. Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin. J Immunol. 2009;182(3):1674–1680.
   PubMed Web of Science ®Google Scholar
• Andreoli L, Fredi M, Nalli C, et al. Clinical significance of IgA anti-cardiolipin and IgA anti-beta2glycoprotein I antibodies. Curr Rheumatol Rep. 2013;15(7):343.
   PubMed Web of Science ®Google Scholar
• Yu F, Tan Y, Zhao MH. Lupus nephritis combined with renal injury due to thrombotic thrombocytopaenic purpura-haemolytic uraemic syndrome. Nephrol Dial Transplant. 2010;25(1):145–152.
   PubMed Web of Science ®Google Scholar
• Tati R, Kristoffersson AC, Stahl AL, et al. Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy. JI. 2013;191(5):2184–2193.
   Google Scholar
• Descombes E, Droz D, Drouet L, et al. Renal vascular lesions in lupus nephritis. Medicine. 1997;76(5):355–368.
   PubMed Web of Science ®Google Scholar
• Pan HF, Fang XH, Wu GC, et al. Anti-neutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus and lupus nephritis. Inflammation. 2008;31(4):260–265.
   PubMed Web of Science ®Google Scholar
• Moeckel GW, Jabs K, Fogo AB. An 11-year-old African-American girl with systemic lupus erythematosus and ANCA-negative renal vasculitis. Am J Kid Dis. 2002;39(2):433–438.
   PubMed Web of Science ®Google Scholar
• Kawabe A, Tsujimura S, Saito K, et al. Efficacy of intravenous cyclophosphamide pulse therapy for P-glycoprotein-expressing b cell-associated active true renal lupus vasculitis in lupus nephritis. Intern Med. 2017;56(12):1575–1580.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Inter Suppl. 2012;2:139–274.
   Web of Science ®Google Scholar
• Li QY, Yu F, Zhou FD, et al. Plasmapheresis is associated with better renal outcomes in lupus nephritis patients with thrombotic microangiopathy: a case series study. Medicine. 2016;95(18):e3595.
   PubMed Web of Science ®Google Scholar
• Legendre CM, Licht C, Muus P, Greenbaum LA, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169–2181.
   PubMed Web of Science ®Google Scholar
• Charneski L, Patel PN. Eculizumab in paroxysmal nocturnal haemoglobinuria. Drugs. 2008;68(10):1341–1346.
   PubMed Web of Science ®Google Scholar
• Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med. 2011;364(26):2561–2563.
   PubMed Web of Science ®Google Scholar
• El-Husseini A, Hannan S, Awad A, et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kid Dis. 2015;65(1):127–130.
   PubMed Web of Science ®Google Scholar
• Sciascia S, Radin M, Yazdany J, et al. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatol Int. 2017;37(8):1249–1255.
   PubMed Web of Science ®Google Scholar
• Pickering MC, Ismajli M, Condon MB, et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford). 2015;54:2286–2288.
   PubMed Web of Science ®Google Scholar
• de Holanda MI, Porto LC, Wagner T, et al. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review. Clin Rheumatol. 2017;36(12):2859–2867.
   PubMed Web of Science ®Google Scholar
• Duggan S. Caplacizumab: first global approval. Drugs. 2018;78(15):1639–1642.
   PubMed Web of Science ®Google Scholar
• Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335–346.
   PubMed Web of Science ®Google Scholar
• Weidenbusch M, Rommele C, Schrottle A, et al. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephr Dial Transpl. 2013;28(1):106–111.
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Fujimura Y, Wada H, et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan. Int J Hematol. 2017;106(1):3–15.
   PubMed Web of Science ®Google Scholar
• Crowley MP, McDonald V, Scully M. Ofatumumab for TTP in a patient with anaphylaxis associated with rituximab. N Engl J Med. 2018;378(1):92–93.
   PubMed Web of Science ®Google Scholar
• Ishii T, Tanaka Y, Kawakami A, et al. Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. Mod Rheumatol. 2018;28(6):986–992.
   PubMed Web of Science ®Google Scholar
• Shortt J, Oh DH, Opat SS. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med. 2013;368(1):90–92.
   PubMed Web of Science ®Google Scholar
• Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833–1838.
   PubMed Web of Science ®Google Scholar
• Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus. 2013;22(1):63–72.
   PubMed Web of Science ®Google Scholar
• Furumoto Y, Smith CK, Blanco L, et al. Tofacitinib ameliorates murine lupus and its associated vascular dysfunction. Arthritis Rheumatol. 2017; 69:148–160.
   PubMed Web of Science ®Google Scholar
• Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69:376–386.
   PubMed Web of Science ®Google Scholar
• Mok CC. Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art. Exp Rev Clin Immunol. 2017;13(7):677–692.
   PubMed Web of Science ®Google Scholar
• Reich HN, Gladman DD, Urowitz MB, et al. Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. Kid Int. 2011;79(8):914–920.
   PubMed Web of Science ®Google Scholar
• Sazliyana S, Mohd Shahrir MS, Kong CT, et al. Implications of immunosuppressive agents in cardiovascular risks and carotid intima media thickness among lupus nephritis patients. Lupus. 2011;20(12):1260–1266.
   PubMed Web of Science ®Google Scholar
• Shimazu H, Kinoshita K, Hino S, et al. Effect of combining ACE inhibitor and statin in lupus-prone mice. Clin Immunol. 2010;136(2):188–196.
   PubMed Web of Science ®Google Scholar